Literature DB >> 30779938

Added value of IgA antibodies against Zika virus non-structural protein 1 in the diagnosis of acute Zika virus infections.

Jens M Warnecke1, Erik Lattwein2, Sandra Saschenbrecker2, Winfried Stöcker2, Wolfgang Schlumberger2, Katja Steinhagen2.   

Abstract

Zika virus (ZIKV) is a mosquito-borne flavivirus posing a public health threat due to its association with neurological complications in newborns and adults. In flavivirus-endemic areas, coming mosquito seasons will require the differentiation of primary versus secondary and acute versus past ZIKV/flavivirus infections. This is complicated by two major difficulties: [i] secondary infections often present with low or undetectable titres of specific IgM and with early-positive IgG, [ii] previous flavivirus infection(s) or vaccinations cause elevated cross-reactivities. Here, we analysed the anti-ZIKV IgA, IgG, and IgM responses at different stages of infection in an endemic setting, scrutinising the diagnostic relevance of specific IgA. Anti-ZIKV antibodies were measured by ELISA based on ZIKV non-structural protein 1 (NS1) in paired sera from 31 patients with suspected primary or (flavivirus-primed) secondary ZIKV infection. The control panel comprised samples from 136 DENV-infected patients. Among ZIKV samples collected 8-16 days after symptom onset, ELISA sensitivities for detecting anti-ZIKV NS1 IgA, IgG, and IgM were 93.5%, 100%, and 48.4%, respectively. The proportion of cases with negative IgM but positive IgA was higher in suspected secondary (61.9%) than in primary (30.0%) ZIKV infections. Combined IgA/IgM detection yielded a sensitivity of 100% at a specificity of 97.1%. In conclusion, at time points after PCR can detect the virus, the determination of anti-ZIKV NS1 IgA may improve the accuracy in diagnosing acute ZIKV infection in flavivirus-endemic regions in the context of both primary and secondary infection, especially when IgM is undetectable.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Flavivirus; Guillain-Barré syndrome; Microcephaly; NS1; Zika virus

Mesh:

Substances:

Year:  2019        PMID: 30779938     DOI: 10.1016/j.jviromet.2019.02.005

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  4 in total

1.  Comparative specificity and sensitivity of NS1-based serological assays for the detection of flavivirus immune response.

Authors:  Erick Mora-Cárdenas; Chiara Aloise; Valentina Faoro; Nataša Knap Gašper; Miša Korva; Ilaria Caracciolo; Pierlanfranco D'Agaro; Tatjana Avšič-Županc; Alessandro Marcello
Journal:  PLoS Negl Trop Dis       Date:  2020-01-29

2.  A need to raise the bar - A systematic review of temporal trends in diagnostics for Japanese encephalitis virus infection, and perspectives for future research.

Authors:  Tehmina Bharucha; Freya M Shearer; Manivanh Vongsouvath; Mayfong Mayxay; Xavier de Lamballerie; Paul N Newton; Nicole Zitzmann; Ernest Gould; Audrey Dubot-Pérès
Journal:  Int J Infect Dis       Date:  2020-03-20       Impact factor: 3.623

3.  Comprehensive response to Usutu virus following first isolation in blood donors in the Friuli Venezia Giulia region of Italy: Development of recombinant NS1-based serology and sensitivity to antiviral drugs.

Authors:  Ilaria Caracciolo; Erick Mora-Cardenas; Chiara Aloise; Tea Carletti; Ludovica Segat; Maria Sole Burali; Alexsia Chiarvesio; Vivianna Totis; Tatjana Avšič-Županc; Eloise Mastrangelo; Giuseppe Manfroni; Pierlanfranco D'Agaro; Alessandro Marcello
Journal:  PLoS Negl Trop Dis       Date:  2020-03-30

4.  Congenital microcephaly unrelated to flavivirus exposure in coastal Kenya.

Authors:  Hellen C Barsosio; John N Gitonga; Henry K Karanja; Doris K Nyamwaya; Donwilliams O Omuoyo; Everlyn Kamau; Mainga M Hamaluba; Joyce U Nyiro; Barnes S Kitsao; Amek Nyaguara; Stella Mwakio; Charles R Newton; Rosemary Sang; Daniel Wright; Eduard J Sanders; Anna C Seale; Charles N Agoti; James A Berkley; Philip Bejon; George M Warimwe
Journal:  Wellcome Open Res       Date:  2019-11-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.